Co-Clinical Imaging Research Resource: PREDICT
H. Charles Manning, Ph.D.
Scott Kopetz, M.D., Ph.D.
Our group participates in NCI's Co-Clinical Imaging Research Resource Program (CIRP). This consortium consists of multiple sites with a common goal of developing quantitative imaging resources for therapeutic co-clinical trials.
Our resource, PET imaging resource to enhance delivery of individualized cancer therapeutics (PREDICT), is focused on PET imaging and radiotracers of glutamine metabolism. The overarching vision for PREDICT is to develop and validate a suite of quantitative imaging tools that facilitate the discovery and optimization of novel, predictive gene expression signatures. PREDICT centers on a parallel co-clinical trial of patients with colorectal cancer (CRC) and patient-derived xenograft (PDX) mouse models of CRC. Imaging is performed using 11C-glutamine/18F-4-fluoro-glutamine and 18F-FSPG. We are correlating the imaging data to treatment response as well as biological correlates such as genetics (RNA-Seq) and immunohistochemistry. We are also developing protocols for standardization of PET in preclinical imaging studies.
This website contains information about the research and members of the MD Anderson Co-Clinical Imaging Research Resource Program. Protocols detailing methods for quantitative preclinical PET imaging and generation and storage of subcutaneous and orthotopic PDX models are under development. Data including patient demographics, PDX models, PET images, treatment response, and correlative biology (RNA-seq and immunohistochemistry) will be accessible through the MIRACCL site when available.
Journal of Nuclear Medicine
First-in-human PET imaging and estimated radiation dosimetry of L-[5-11C]-glutamine in patients with metastatic colorectal cancer.
Cohen AS, Grudzinski J, Smith GT, Peterson TE, Whisenant JG, Hickman TL, Ciombor KK, Cardin D, Eng C, Goff LW, Das S, Coffey RJ, Berlin JD, Manning HC. J Nucl Med. 2021 Apr 30:jnumed.120.261594. doi: 10.2967/jnumed.120.261594. Online ahead of print. PMID: 33931465
Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer.
Cohen AS, Geng L, Zhao P, Fu A, Schulte ML, Graves-Deal R, Washington MK, Berlin J, Coffey RJ, Manning HC. Transl Oncol. 2020 Oct;13(10):100828. doi: 10.1016/j.tranon.2020.100828. Epub 2020 Jul 8. PMID: 32652471
Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine.
Shoghi KI, Badea CT, Blocker SJ, Chenevert TL, Laforest R, Lewis MT, Luker GD, Manning HC, Marcus DS, Mowery YM, Pickup S, Richmond A, Ross BD, Vilgelm AE, Yankeelov TE, Zhou R. Tomography. 2020 Sep;6(3):273-287. doi: 10.18383/j.tom.2020.00023. PMID: 32879897
Bioorganic & Medicinal Chemistry Letters
N-[18F]-Fluoroacetylcrizotinib: A Potentially Potent and Selective PET Tracer for Molecular Imaging of Non–small Cell Lung Cancer.
Buck, JR, Saleh S, Claus T, Lovly C, Hight MR, Nickels ML, Tantay MN, Manning HC. Bio Org Med Chem Let 30(16), 8/2020. PMCID: PMC7357882
Related Departments & Programs
H. Charles Manning, Ph.D.
Professor, Department of Cancer Systems Imaging
Director, Cyclotron Radiochemistry Facility
Scientific Director, Center for Advanced Biomedical Imaging (CABI)
Sr. Administrative Assistant